Researchers have developed a nanoparticle, made up of siRNAs around a gold core, that could cross the blood-brain barrier and, in animals, silence a gene that is overexpressed most cases of glioblastoma multiforme.
Bleeding and clotting are considered two sides of the same coin, and basically, of course, they are. But by selectively blocking specific aspects of integrin signaling, researchers have reported a way to block clotting without increasing the risk of bleeding.
By first looking at the tumor of one specific lung cancer patient in prodigious detail, and validating their findings a large number of cell lines, researchers have achieved two things.
Two separate teams, one from Yale University and another from the German Charite Hospital and Stanford University, have reported that allergic reactions to bee stings can protect mice from later, larger doses of bee venom, suggesting that allergies may serve a protective effect rather than being a misdirected immune response.
Scientists have identified a key signaling molecule that the liver uses to influence muscle metabolism, and shown that such signaling has its own circadian rhythms.
Scientists have reported evidence that the brain’s equivalent of the lymphatic system, called the “glymph” system, undergoes massive structural changes with the sleep-wake cycle, and that those changes enable it to dispose of toxic waste proteins.
Some therapeutic areas – rare diseases, the more intractable cancers – have a need for more intense drug development efforts because there is nothing that works for them.
A team from South San Francisco based Cytomx Therapeutics Inc. reported today that it has developed an EGFR-targeting “probody” that was activated specifically in the tumor microenvironment, allowing its delivery at higher doses than conventional antibodies to both mice and primates.
